A to Z / Metabolic / weight loss
Pramlintide
Also known as Symlin.
Best known for The approved amylin medicine, less widely known
Evidence★★★★☆
Safety dataWell characterised
Route Injectable, with meals
United StatesFDA approved (adjunct in diabetes)
AustraliaSchedule 4
as at 16 September 2026
What it is
Pramlintide is a synthetic analogue of amylin, approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes.{{CITE:fda-label-symlin}} It was the proof of concept for the entire amylin class, and paved the way for cagrilintide.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with Cagrilintide, CagriSema, Insulin, Semaglutide
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Pramlintide. It is not medical advice and not a recommendation to use it.